Are we ready for universal influenza vaccination in paediatrics? (Q35661210)

9 August 2017

1 reference

title

Are we ready for universal influenza vaccination in paediatrics? (English)

1 reference

9 August 2017

1

Nicola Principi

1 reference

9 August 2017

Susanna Esposito

2

1 reference

9 August 2017

publication date

1 February 2004

1 reference

Lancet Infectious Diseases

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

75-83

1 reference

Febrile respiratory tract illness in a 3-month old infant

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Technical report: Reduction of the influenza burden in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

1 reference

7 January 2021

The global impact of influenza on morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

New recommendations for influenza vaccination for children and pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenza vaccination for healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenza and the rates of hospitalization for respiratory disease among infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Socioeconomic impact of influenza on healthy children and their families

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenza A and B virus infections in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Burden of disease--implications for future research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The epidemiology and history of influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Longitudinal studies of types A and B influenza among Seattle schoolchildren and families, 1968-74.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Encephalitis and encephalopathy associated with an influenza epidemic in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

A study of influenza and influenza-related complications among children in a large US health insurance plan database

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The burden of influenza illness in children with asthma and other chronic medical conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Impact of respiratory virus infections on persons with chronic underlying conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenza vaccines: new developments.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Pandemic influenza and the global vaccine supply.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Virosomal adjuvanted antigen delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Virosome influenza vaccine in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Inflexal V a trivalent virosome subunit influenza vaccine: production

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenza immunization practices among pediatric oncologists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Response to influenza immunisation during treatment for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Immunization against influenza in children with cancer: results of a three-dose trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Vaccination and HIV: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Effect of influenza vaccination on disease progression among HIV-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Guillain-Barré Syndrome and the 1978–1979 Influenza Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The safety of inactivated influenza vaccine in adults and children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Does influenza vaccination prevent asthma exacerbations in children?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Current issues with influenza vaccination in egg allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Validity of specific IgE antibodies in children with egg allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Safe administration of influenza vaccine to patients with egg allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Direct and indirect effects in vaccine efficacy and effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The Japanese experience with vaccinating schoolchildren against influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Modification of an Outbreak of Influenza in Tecumseh, Michigan by Vaccination of Schoolchildren

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Economic impact of influenza vaccination in preschool children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Potential cost savings attributable to influenza vaccination of school-aged children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

The economic impact of pandemic influenza in the United States: priorities for intervention.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Cost-effectiveness study on influenza prevention in Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Cost-effectiveness of influenza vaccination in high-risk children in Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Predictors of influenza virus vaccination status in hospitalized children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Influenza vaccination coverage level at a cystic fibrosis center

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

A computerized reminder strategy is effective for annual influenza immunization of children with asthma or reactive airway disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

Time spent by primary care practices on pediatric influenza vaccination visits: implications for universal influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2900926-0

7 January 2021

10.1016/S1473-3099(04)00926-0

Identifiers

DOI

1 reference

9 August 2017

1 reference